# Celestica Inc: financial statements, quarterly CLS · NYSE · CIK 1030894 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/cls.md) · [Financials](/companies/cls/financials.md) · [Filings](/companies/cls/filings.md) · [Insiders](/companies/cls/insiders.md) Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/cls/financials.md?period=annual). ## Income statement | Line item | Unit | period not labelled (2024-03-31) | period not labelled (2024-06-30) | period not labelled (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [2,209](/filings/0001030894-25-000028.md) | [2,392](/filings/0001030894-25-000047.md) | [2,500](/filings/0001030894-25-000053.md) | [2,546 d](/filings/0001030894-26-000011.md) | [2,649](/filings/0001030894-26-000032.md) | [2,893](/filings/0001030894-26-000044.md) | [3,194](/filings/0001030894-26-000050.md) | [3,655 d](/filings/0001030894-26-000011.md) | [4,047](/filings/0001030894-26-000032.md) | [4,699](/filings/0001030894-26-000044.md) | [5,830](/filings/0001030894-26-000050.md) | | Cost of revenue | $m | [1,987](/filings/0001030894-25-000028.md) | [2,138](/filings/0001030894-25-000047.md) | [2,239](/filings/0001030894-25-000053.md) | [2,249 d](/filings/0001030894-26-000011.md) | [2,375](/filings/0001030894-26-000032.md) | [2,522](/filings/0001030894-26-000044.md) | [2,778](/filings/0001030894-26-000050.md) | [3,222 d](/filings/0001030894-26-000011.md) | [3,610](/filings/0001030894-26-000032.md) | [4,121](/filings/0001030894-26-000044.md) | [5,189](/filings/0001030894-26-000050.md) | | Gross profit | $m | [222](/filings/0001030894-25-000028.md) | [254](/filings/0001030894-25-000047.md) | [261](/filings/0001030894-25-000053.md) | [297 d](/filings/0001030894-26-000011.md) | [274](/filings/0001030894-26-000032.md) | [371](/filings/0001030894-26-000044.md) | [416](/filings/0001030894-26-000050.md) | [433 d](/filings/0001030894-26-000011.md) | [437](/filings/0001030894-26-000032.md) | [578](/filings/0001030894-26-000044.md) | [641](/filings/0001030894-26-000050.md) | | Research and development | $m | [16.5](/filings/0001030894-25-000028.md) | [19.4](/filings/0001030894-25-000047.md) | [18.7](/filings/0001030894-25-000053.md) | [23.4 d](/filings/0001030894-26-000011.md) | [17.6](/filings/0001030894-26-000032.md) | [34.0](/filings/0001030894-26-000044.md) | [36.4](/filings/0001030894-26-000050.md) | [30.2 d](/filings/0001030894-26-000011.md) | [41.2](/filings/0001030894-26-000032.md) | [46.3](/filings/0001030894-26-000044.md) | [51.2](/filings/0001030894-26-000050.md) | | Selling, general and administrative | $m | [64.8](/filings/0001030894-25-000028.md) | [79.3](/filings/0001030894-25-000047.md) | [91.8](/filings/0001030894-25-000053.md) | [57.6 d](/filings/0001030894-26-000011.md) | [113](/filings/0001030894-26-000032.md) | [38.9](/filings/0001030894-26-000044.md) | [38.4](/filings/0001030894-26-000050.md) | [70.1 d](/filings/0001030894-26-000011.md) | [117](/filings/0001030894-26-000032.md) | [58.1](/filings/0001030894-26-000044.md) | [118](/filings/0001030894-26-000050.md) | | Operating income | $m | [126](/filings/0001030894-25-000028.md) | [133](/filings/0001030894-25-000047.md) | [138](/filings/0001030894-25-000053.md) | [203 d](/filings/0001030894-26-000011.md) | [129](/filings/0001030894-26-000032.md) | [273](/filings/0001030894-26-000044.md) | [325](/filings/0001030894-26-000050.md) | [314 d](/filings/0001030894-26-000011.md) | [272](/filings/0001030894-26-000032.md) | [458](/filings/0001030894-26-000044.md) | [460](/filings/0001030894-26-000050.md) | | Interest expense | $m | [14.0](/filings/0001030894-25-000028.md) | [15.0](/filings/0001030894-25-000047.md) | [11.2](/filings/0001030894-25-000053.md) | [11.9 d](/filings/0001030894-26-000011.md) | [13.7](/filings/0001030894-26-000032.md) | [14.4](/filings/0001030894-26-000044.md) | [13.8](/filings/0001030894-26-000050.md) | [9.4 d](/filings/0001030894-26-000011.md) | [16.0](/filings/0001030894-26-000032.md) | [21.2](/filings/0001030894-26-000044.md) | [24.1](/filings/0001030894-26-000050.md) | | Income tax | $m | [13.4](/filings/0001030894-25-000028.md) | [18.5](/filings/0001030894-25-000047.md) | [34.5](/filings/0001030894-25-000053.md) | [37.8 d](/filings/0001030894-26-000011.md) | [27.5](/filings/0001030894-26-000032.md) | [46.3](/filings/0001030894-26-000044.md) | [43.1](/filings/0001030894-26-000050.md) | [33.8 d](/filings/0001030894-26-000011.md) | [44.0](/filings/0001030894-26-000032.md) | [72.8](/filings/0001030894-26-000044.md) | [58.6](/filings/0001030894-26-000050.md) | | Net income | $m | [91.8](/filings/0001030894-25-000028.md) | [95.0](/filings/0001030894-25-000047.md) | [89.5](/filings/0001030894-25-000053.md) | [152 d](/filings/0001030894-26-000011.md) | [86.2](/filings/0001030894-26-000032.md) | [211](/filings/0001030894-26-000044.md) | [268](/filings/0001030894-26-000050.md) | [268 d](/filings/0001030894-26-000011.md) | [212](/filings/0001030894-26-000032.md) | [369](/filings/0001030894-26-000044.md) | [397](/filings/0001030894-26-000050.md) | | Diluted EPS | $ per share | [0.77](/filings/0001030894-25-000028.md) | [0.80](/filings/0001030894-25-000047.md) | [0.75](/filings/0001030894-25-000053.md) | not reported | [0.74](/filings/0001030894-26-000032.md) | [1.82](/filings/0001030894-26-000044.md) | [2.31](/filings/0001030894-26-000050.md) | not reported | [1.83](/filings/0001030894-26-000032.md) | [3.17](/filings/0001030894-26-000044.md) | [3.26](/filings/0001030894-26-000050.md) | | Basic EPS | $ per share | [0.77](/filings/0001030894-25-000028.md) | [0.80](/filings/0001030894-25-000047.md) | [0.76](/filings/0001030894-25-000053.md) | not reported | [0.74](/filings/0001030894-26-000032.md) | [1.83](/filings/0001030894-26-000044.md) | [2.33](/filings/0001030894-26-000050.md) | not reported | [1.85](/filings/0001030894-26-000032.md) | [3.21](/filings/0001030894-26-000044.md) | [3.30](/filings/0001030894-26-000050.md) | - Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax - Cost of revenue: us-gaap:CostOfGoodsAndServicesSold - Gross profit: us-gaap:GrossProfit - Research and development: us-gaap:ResearchAndDevelopmentExpense - Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense - Operating income: us-gaap:OperatingIncomeLoss - Interest expense: us-gaap:InterestExpenseNonoperating - Income tax: us-gaap:IncomeTaxExpenseBenefit - Net income: us-gaap:NetIncomeLoss - Diluted EPS: us-gaap:EarningsPerShareDiluted - Basic EPS: us-gaap:EarningsPerShareBasic ## Balance sheet | Line item | Unit | FY2023 (2023-12-31) | period not labelled (2024-03-31) | period not labelled (2024-06-30) | period not labelled (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Cash and equivalents | $bn | [0.4](/filings/0001030894-25-000014.md) | not reported | not reported | not reported | [0.4](/filings/0001030894-26-000011.md) | [0.3](/filings/0001030894-25-000028.md) | [0.3](/filings/0001030894-25-000047.md) | [0.3](/filings/0001030894-25-000053.md) | [0.6](/filings/0001030894-26-000050.md) | [0.4](/filings/0001030894-26-000032.md) | [0.5](/filings/0001030894-26-000044.md) | [4.0](/filings/0001030894-26-000050.md) | | Current assets | $bn | [4.5](/filings/0001030894-25-000014.md) | not reported | not reported | not reported | [4.5](/filings/0001030894-26-000011.md) | [4.4](/filings/0001030894-25-000028.md) | [4.8](/filings/0001030894-25-000047.md) | [5.1](/filings/0001030894-25-000053.md) | [5.7](/filings/0001030894-26-000050.md) | [6.4](/filings/0001030894-26-000032.md) | [7.6](/filings/0001030894-26-000044.md) | [12.5](/filings/0001030894-26-000050.md) | | Total assets | $bn | [5.9](/filings/0001030894-25-000014.md) | not reported | not reported | not reported | [6.0](/filings/0001030894-26-000011.md) | [5.8](/filings/0001030894-25-000028.md) | [6.2](/filings/0001030894-25-000047.md) | [6.6](/filings/0001030894-25-000053.md) | [7.2](/filings/0001030894-26-000050.md) | [8.3](/filings/0001030894-26-000032.md) | [9.8](/filings/0001030894-26-000044.md) | [15.1](/filings/0001030894-26-000050.md) | | Current liabilities | $bn | [3.2](/filings/0001030894-25-000014.md) | not reported | not reported | not reported | [3.0](/filings/0001030894-26-000011.md) | [3.1](/filings/0001030894-25-000028.md) | [3.3](/filings/0001030894-25-000047.md) | [3.5](/filings/0001030894-25-000053.md) | [3.9](/filings/0001030894-26-000050.md) | [5.1](/filings/0001030894-26-000032.md) | [6.2](/filings/0001030894-26-000044.md) | [7.8](/filings/0001030894-26-000050.md) | | Total liabilities | $bn | [4.1](/filings/0001030894-25-000014.md) | not reported | not reported | not reported | [4.1](/filings/0001030894-26-000011.md) | [4.3](/filings/0001030894-25-000028.md) | [4.5](/filings/0001030894-25-000047.md) | [4.6](/filings/0001030894-25-000053.md) | [5.0](/filings/0001030894-26-000050.md) | [6.2](/filings/0001030894-26-000032.md) | [7.3](/filings/0001030894-26-000044.md) | [8.9](/filings/0001030894-26-000050.md) | | Shareholders' equity | $bn | [1.8](/filings/0001030894-26-000011.md) | [1.7](/filings/0001030894-25-000047.md) | [1.8](/filings/0001030894-25-000053.md) | [1.8](/filings/0001030894-25-000053.md) | [1.9](/filings/0001030894-26-000050.md) | [1.6](/filings/0001030894-26-000044.md) | [1.8](/filings/0001030894-26-000050.md) | [2.0](/filings/0001030894-26-000050.md) | [2.2](/filings/0001030894-26-000050.md) | [2.1](/filings/0001030894-26-000044.md) | [2.5](/filings/0001030894-26-000050.md) | [6.2](/filings/0001030894-26-000050.md) | - Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue - Current assets: us-gaap:AssetsCurrent - Total assets: us-gaap:Assets - Current liabilities: us-gaap:LiabilitiesCurrent - Total liabilities: us-gaap:Liabilities - Shareholders' equity: us-gaap:StockholdersEquity ## Cash flow | Line item | Unit | period not labelled (2024-03-31) | period not labelled (2024-06-30) | period not labelled (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Operating cash flow | $m | [108](/filings/0001030894-25-000028.md) | [99.6](/filings/0001030894-25-000047.md) | [123](/filings/0001030894-25-000053.md) | [143 d](/filings/0001030894-26-000011.md) | [130](/filings/0001030894-26-000032.md) | [152](/filings/0001030894-26-000044.md) | [126](/filings/0001030894-26-000050.md) | [251 d](/filings/0001030894-26-000011.md) | [356](/filings/0001030894-26-000032.md) | [411](/filings/0001030894-26-000044.md) | [390](/filings/0001030894-26-000050.md) | | Capital expenditure | $m | [40.4](/filings/0001030894-25-000028.md) | [36.9](/filings/0001030894-25-000047.md) | [46.0](/filings/0001030894-25-000053.md) | [47.6 d](/filings/0001030894-26-000011.md) | [36.7](/filings/0001030894-26-000032.md) | [32.5](/filings/0001030894-26-000044.md) | [37.3](/filings/0001030894-26-000050.md) | [94.7 d](/filings/0001030894-26-000011.md) | [230](/filings/0001030894-26-000032.md) | [264](/filings/0001030894-26-000044.md) | [274](/filings/0001030894-26-000050.md) | | Share repurchases | $m | [16.5](/filings/0001030894-25-000028.md) | [10.0](/filings/0001030894-25-000047.md) | [100](/filings/0001030894-25-000053.md) | [25.5 d](/filings/0001030894-26-000011.md) | [77.7](/filings/0001030894-26-000032.md) | [40.0](/filings/0001030894-26-000044.md) | [0.0](/filings/0001030894-26-000050.md) | [35.7 d](/filings/0001030894-26-000011.md) | [22.6](/filings/0001030894-26-000032.md) | [0.0](/filings/0001030894-26-000044.md) | [0.0](/filings/0001030894-26-000050.md) | - Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities - Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets - Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock ## Shares | Line item | Unit | period not labelled (2024-03-31) | period not labelled (2024-06-30) | period not labelled (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Diluted shares (weighted) | millions of shares | [119](/filings/0001030894-25-000028.md) | [119](/filings/0001030894-25-000047.md) | [119](/filings/0001030894-25-000053.md) | [117](/filings/0001030894-26-000032.md) | [116](/filings/0001030894-26-000044.md) | [116](/filings/0001030894-26-000050.md) | [116](/filings/0001030894-26-000032.md) | [116](/filings/0001030894-26-000044.md) | [122](/filings/0001030894-26-000050.md) | - Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding Shares outstanding: 126,111,808 at 2026-10-21, from the cover of the [10-Q filed 2026-10-26](/filings/0001030894-26-000050.md) (dei:EntityCommonStockSharesOutstanding). Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 26, 2026, 16:46 ET. No prices; not investment advice.